Literature DB >> 9118038

The relationship between telomere length and therapy-associated cytogenetic responses in patients with chronic myeloid leukemia.

H Iwama1, K Ohyashiki, J H Ohyashiki, S Hayashi, K Kawakubo, J W Shay, K Toyama.   

Abstract

BACKGROUND: Chronic myeloid leukemia (CML) is a clonal disease with specific cytogenetic changes involving the Philadelphia (Ph) translocation. The authors examined the relationship between telomere length (terminal restriction fragment [TRF]) and therapy-associated cytogenetic responses in CML patients.
METHODS: The authors examined the telomere length and telomerase activity in 44 patients with Ph-positive CML in the chronic phase. TRF was determined by Southern blot analysis using the (TTAGGG)4 probe and telomerase activity was assessed by the telomeric repeat amplification protocol and fluorescent-labeled primers.
RESULTS: At the time of CML diagnosis, 19 patients had TRFs within the age-matched normal range (mean +/- 2 x standard deviation [SD]) and the remaining 25 patients had TRFs shorter than the age-matched normal range (< mean +/- 2 x SD). Hematologic findings, including leukocyte count, hemoglobin level, platelet count, and percentage of bone marrow blasts at the time of diagnosis did not significantly differ between patients with normal and shortened TRFs; however, those with shortened TRFs had high levels of telomerase activity (P = 0.045). In a group of patients treated with alpha-interferon (n = 32), those with normal TRFs had a significantly lower frequency of blast crises (P = 0.0328), a significantly higher incidence of cytogenetic responses (P = 0.0185), and a favorable prognosis (P < 0.01) compared with those with shortened TRFs.
CONCLUSIONS: These findings suggest that normal TRFs in a small number of CML patients at the time of diagnosis may have a significant amount of normal stem cells remaining. The authors suggest that normal TRFs at the time of diagnosis indicate a subset of CML patients who may respond favorably to alpha-interferon therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9118038     DOI: 10.1002/(sici)1097-0142(19970415)79:8<1552::aid-cncr17>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  The Effect of Cancer Treatments on Telomere Length: A Systematic Review of the Literature.

Authors:  Lisa Gallicchio; Shahinaz M Gadalla; John D Murphy; Naoko I Simonds
Journal:  J Natl Cancer Inst       Date:  2018-10-01       Impact factor: 13.506

Review 2.  The role of telomere biology in bone marrow failure and other disorders.

Authors:  Sharon A Savage; Blanche P Alter
Journal:  Mech Ageing Dev       Date:  2007-11-19       Impact factor: 5.432

Review 3.  Association between telomere length and survival in cancer patients: a meta-analysis and review of literature.

Authors:  Xinsen Xu; Kai Qu; Qing Pang; Zhixin Wang; Yanyan Zhou; Chang Liu
Journal:  Front Med       Date:  2016-05-16       Impact factor: 4.592

Review 4.  Imatinib mesylate in combination with other chemotherapeutic agents for chronic myelogenous leukemia.

Authors:  Tetsuzo Tauchi; Kazuma Ohyashiki
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

Review 5.  Methods for the molecular analysis of cancer. An overview.

Authors:  Ken Mills
Journal:  Mol Biotechnol       Date:  2003-02       Impact factor: 2.695

6.  Telomerase detection in the diagnosis and prognosis of cancer.

Authors:  Eiso Hiyama; Keiko Hiyama
Journal:  Cytotechnology       Date:  2004-06       Impact factor: 2.058

7.  Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms.

Authors:  L Bernard; C Belisle; L Mollica; S Provost; D-C Roy; D G Gilliland; R L Levine; L Busque
Journal:  Leukemia       Date:  2008-11-13       Impact factor: 11.528

8.  Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients.

Authors:  Giovanni Caocci; Marianna Greco; Giuseppe Delogu; Christian Secchi; Bruno Martino; Claudia Labate; Elisabetta Abruzzese; Malgorzata Monika Trawinska; Sara Galimberti; Federica Orru; Claudio Fozza; Carlo Gambacorti Passerini; Francesco Galimi; Giorgio La Nasa
Journal:  J Hematol Oncol       Date:  2016-07-29       Impact factor: 17.388

9.  Three-dimensional nuclear telomere architecture and differential expression of aurora kinase genes in chronic myeloid leukemia to measure cell transformation.

Authors:  Fábio Morato de Oliveira; Valderez Ravaglio Jamur; Lismeri Wuicik Merfort; Aline Rangel Pozzo; Sabine Mai
Journal:  BMC Cancer       Date:  2022-09-29       Impact factor: 4.638

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.